JOHNSON DAVID LEE 4
4 · Vera Therapeutics, Inc. · Filed Feb 20, 2025
Insider Transaction Report
Form 4
JOHNSON DAVID LEE
Chief Operating Officer
Transactions
- Award
Class A Common Stock
2025-02-18+26,900→ 26,900 total - Award
Stock Option (right to buy)
2025-02-18+53,800→ 53,800 totalExercise: $29.18Exp: 2035-02-17→ Class A Common Stock (53,800 underlying)
Footnotes (2)
- [F1]Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date.
- [F2]1/48 of the shares subject to the stock option will vest and become exercisable on March 18, 2025, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.